Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130845 · ClinicalTrials.gov registry record · Phase 3
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
A Phase 3 study of Diabetic Retinopathy, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 312
- Enrollment target
- 1
- Study location
NCT00130845: Completed Phase 3 study of Diabetic Retinopathy, sponsored by Novartis.
NCT00130845 is a Phase 3 study of Diabetic Retinopathy that has completed, run by Novartis. The registered enrollment target is 312 participants, below the 1,671-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00130845, a Phase 3 study of Diabetic Retinopathy, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 312 participants
- Enrollment target
- 1
- Study location
Study Summary
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Octreotide Acetate in Microspheres
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2000-02 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
What the finished NCT00130845 record still lists
NCT00130845 is an interventional study that assigns participants to a tested intervention. The registered 312 participants enrollment target is mid-sized for trials with a published cap, below the 1,671-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00130845 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00130845 about?
NCT00130845 is a clinical study titled "Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy". The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and p...
What is the current status of trial NCT00130845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 312 participants. The study started on 2000-02. Estimated completion is 2005-12.
What conditions does trial NCT00130845 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT00130845?
The interventions under investigation include: Placebo (DRUG), Octreotide Acetate in Microspheres (DRUG).
Who is sponsoring clinical trial NCT00130845?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00130845 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00130845's enrollment target sits among peer trials
312 21st of 57 higher than 37 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
COMPLETED · Phase 3
-
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
COMPLETED · Phase 3
-
Anti-VEGF Treatment for Prevention of PDR/DME
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04984551 · 312 participants · Phase 2
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
- NCT04999904 · 312 participants · NA
A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability
- NCT05220332 · 312 participants · NA
Church-based Intervention to Improve Blood Pressure in African Americans
- NCT05434234 · 312 participants · Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia